

Venus Remedies bags additional patent for Vancoplus from US

- ✧ It is an additional patent for Vancoplus from USPTO, with broader coverage for use and method of treatment
- ✧ The formulation will be commercialized in the US market through technology transfer/outlicensing of exclusive marketing rights route
- ✧ Valid till 2032

Venus Remedies Ltd, a research-oriented global pharmaceutical company, has bagged additional patent for Vancoplus from USPTO. Vancoplus is an antibiotic adjuvant entity effective in one the most deadly resistance by Methicillin Resistant *Staphylococcus Aureus* (MRSA). Developed by the Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than 9 per cent of success rate.

Quoting on patent, Dr Manu Chaudhary, Joint managing Director, Venus Remedies said, "The patent is valid till 2032. We have already initiated process for pre IND meeting with US FDA and we are quite optimistic to get fast track approval for this product because MRSA is under the list of limited pathogens identified under GAIN act by FDA and Vancoplus falls in that QIDP category."

Venus Remedies already have product patent for Vancoplus from US PTO, this additional patent with broader coverage for use and method of treatment will be beneficial for the company. The formulation will be commercialized in the US market through technology transfer/outlicensing of exclusive marketing rights route and we are open for such deals.

VANCOPLUS is a novel antibiotic adjuvant entity highly effective against MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens. Vancoplus is the best and safest option to address such infections. it is also active against different mechanisms of resistance such as Cell Membrane impermeability, Efflux pumps, Biofilms, which no other therapeutic options available are able to address.

It took the VMRC more than seven years to develop this product, which has received an overwhelming response from the medical fraternity in India since it was launched in the country four years ago and the product is growing with more than 25% CAGR in Indian market.

In USA alone, MRSA is associated with a staggering 90,000 infections and an estimated 19,000 deaths annually. Global Antibacterials Market which is slated to reach approx US \$64 bn by the year 2018 with a growth rate of 7.5%. Vancoplus is segmented in Hospital Treated Infection Market which is growing at a rate of 2.7%. By taking sales of competitors brands in 2013 as addressable market for Vancoplus, which stands at US \$Mn 2610.

"In view of the steep rise in the prevalence of MRSA, VRSA and hGISA infections, Vancoplus will be the need of the hour, due to its high potency against these infections and

mixed bacterial infection of gram negative & gram positive pathogens. We have developed Vancoplus to address this unmet need,” said Dr Manu Chaudhary, Joint Managing Director, Venus Remedies Ltd, and Director, Research, VMRC.

Besides this, Venus has also secured US patent for its novel research products ELORES, Potentox and Achnil.